181 related articles for article (PubMed ID: 28344207)
1. Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease - Recent Insights Focusing on Angiogenesis and Neovascularization.
Lei Y; Hu L; Yang G; Piao L; Jin M; Cheng X
Circ J; 2017 May; 81(6):770-776. PubMed ID: 28344207
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
3. MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression.
Shih CM; Chen YH; Lin YW; Tsao NW; Wu SC; Kao YT; Chiang KH; Li CY; Chang NC; Lin CY; Huang CY; Lin FY
Curr Med Chem; 2014 Jun; 21(17):2012-22. PubMed ID: 24059225
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Fadini GP; Avogaro A
Vascul Pharmacol; 2011; 55(1-3):10-6. PubMed ID: 21664294
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.
Chrysant SG; Chrysant GS
Am J Cardiol; 2012 Jun; 109(11):1681-5. PubMed ID: 22425330
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
Anderluh M; Kocic G; Tomovic K; Kocic R; Deljanin-Ilic M; Smelcerovic A
Pharmacol Ther; 2016 Nov; 167():100-107. PubMed ID: 27484974
[TBL] [Abstract][Full Text] [Related]
7. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
Davidson MH
Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792
[TBL] [Abstract][Full Text] [Related]
8. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Singh AK; Jatwa R; Purohit A; Ram H
J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury.
Yoon AH; Ye Y; Birnbaum Y
J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):417-25. PubMed ID: 24607763
[TBL] [Abstract][Full Text] [Related]
10. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy.
Hasan AA; Hocher B
J Mol Endocrinol; 2017 Jul; 59(1):R1-R10. PubMed ID: 28420715
[TBL] [Abstract][Full Text] [Related]
11. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
12. Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.
Packer M
Cardiovasc Diabetol; 2018 Jan; 17(1):9. PubMed ID: 29310647
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease.
Makino Y; Fujita Y; Haneda M
Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):67-73. PubMed ID: 25415611
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
15. Role of Dipeptidyl Peptidase-4 in Atherosclerotic Cardiovascular Disease in Humans and Animals with Chronic Stress.
Piao L; Li Y; Narisawa M; Shen X; Cheng XW
Int Heart J; 2021 May; 62(3):470-478. PubMed ID: 33994495
[TBL] [Abstract][Full Text] [Related]
16. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Bae EJ
Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.
Zhao Y; Yang L; Zhou Z
J Diabetes; 2014 Jan; 6(1):21-9. PubMed ID: 23683065
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
19. The potential for renoprotection with incretin-based drugs.
Tanaka T; Higashijima Y; Wada T; Nangaku M
Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
[TBL] [Abstract][Full Text] [Related]
20. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
Omar B; Ahrén B
Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
